GH Secretagogue Risk Profiles: Known and Unknown

GH Peptide Safety

6.5% CHF rate

In one hip fracture trial, 6.5% of elderly patients on MK-677 developed congestive heart failure versus 1.7% on placebo, forcing early termination.

Adunsky et al., Archives of Gerontology and Geriatrics, 2011

Adunsky et al., Archives of Gerontology and Geriatrics, 2011

View as image

Growth hormone secretagogues have been studied in human clinical trials since the mid-1990s. Over 11 different compounds, from injectable peptides like GHRP-6 and ipamorelin to the oral agent MK-677 (ibutamoren), have entered controlled human testing.^[1] None have achieved FDA approval as growth hormone secretagogues. The reasons vary by compound, but a recurring pattern emerges: promising anabolic effects accompanied by metabolic trade-offs that prove difficult to separate. Understanding these risk profiles requires looking at each compound class individually, because the differences between them are clinically meaningful. If you are looking for broader context on MK-677's insulin resistance trade-off, our pillar article covers that in depth.

What makes each secretagogue different

Growth hormone secretagogues share a common mechanism: they bind the ghrelin receptor (GHS-R1a) to trigger pulsatile GH release from the pituitary.^[1] But their off-target effects diverge substantially.

GHRP-6 and GHRP-2 are injectable hexapeptides that reliably increase GH but also raise ACTH and cortisol levels.^[3] GHRP-6 additionally stimulates strong hunger by activating ghrelin signaling pathways. These off-target hormonal effects limited their clinical development.

Ipamorelin broke from this pattern. In the pivotal 1998 characterization study by Raun and colleagues, ipamorelin released GH with potency comparable to GHRP-6 but did not increase ACTH or cortisol at any dose tested. Even at concentrations 200-fold above the effective GH-releasing dose, cortisol remained at levels indistinguishable from GHRH stimulation alone.^[3] FSH, LH, PRL, and TSH were also unaffected. This selectivity profile remains unique among GH secretagogues and helps explain why ipamorelin has advanced into clinical studies for postoperative gut recovery.^[9]

MK-677 (ibutamoren) is the most extensively studied secretagogue because it is orally active. This practical advantage enabled large, long-duration trials. But the MK-677 data also reveal the clearest picture of secretagogue risks, because longer exposure periods and larger sample sizes surface adverse events that short peptide studies miss.

Hexarelin is the most potent GH-releasing peptide but shares the ACTH/cortisol elevation seen with GHRP-6. Research has pivoted toward its cardioprotective effects, which appear independent of GH release.

Insulin resistance and glucose disruption

The most consistent adverse signal across GH secretagogue trials is impaired glucose metabolism. This is not a surprise: growth hormone itself is a counter-regulatory hormone that opposes insulin action. The question is whether secretagogue-induced GH elevation produces clinically meaningful insulin resistance.

In the longest controlled trial, Nass and colleagues randomized 65 healthy adults aged 60-81 to MK-677 25 mg or placebo daily for 2 years.^[2] Fasting blood glucose increased by an average of 0.3 mmol/L (5 mg/dL) in the MK-677 group (P = 0.015), and insulin sensitivity decreased. Fat-free mass increased by 1.1 kg versus a 0.5 kg decline on placebo (P < 0.001), but this did not translate into improved strength or function.

Svensson's 1998 study of 24 obese men treated with MK-677 25 mg daily for 8 weeks found similar metabolic trade-offs.^[4] Serum IGF-1 increased approximately 40%, and fat-free mass rose significantly. But oral glucose tolerance testing at both 2 and 8 weeks showed impaired glucose homeostasis. Fasting glucose and insulin concentrations remained normal, meaning the standard fasting blood work a clinician might order would miss the deterioration entirely.

White and colleagues saw the same pattern in a larger trial of 395 adults aged 65-84 receiving a different oral secretagogue, capromorelin, in multiple dosing regimens.^[5] Adverse events included small increases in fasting glucose, glycosylated hemoglobin, and indices of insulin resistance. The study was terminated early per predetermined treatment effect criteria, but 315 subjects completed 6 months.

The practical concern: secretagogues produce body composition improvements (more lean mass, sometimes more bone turnover) at the cost of pushing glucose metabolism in a pre-diabetic direction. For individuals already carrying metabolic risk factors, this trade-off may be unfavorable. The Sigalos review noted that "development of insulin resistance is of concern because it predisposes a patient to diabetes mellitus and vascular disease."^[1]

The congestive heart failure signal

The most alarming safety signal from any GH secretagogue trial came from the Adunsky 2011 study of MK-677 in elderly patients recovering from hip fracture.^[6] Among 123 patients randomized to MK-677 25 mg or placebo, 4 patients in the MK-677 group (6.5%) and 1 in the placebo group (1.7%) developed congestive heart failure. The trial was terminated early, and the authors concluded MK-677 has "an unfavorable safety profile in this patient population."

Context matters here. The subjects were elderly (mean age ~80), had just suffered hip fractures, and likely had pre-existing cardiovascular vulnerability. GH and IGF-1 can promote fluid retention, and the edema associated with GH-axis activation may have pushed borderline hearts into failure. The Nass 2-year study in healthier older adults reported transient mild lower-extremity edema but no CHF events.^[2]

The hip fracture CHF signal has not been replicated in other populations. But it has not been ruled out either, because no trial since has enrolled a comparably frail population. The 563-patient Alzheimer's disease trial of MK-677 ran for 12 months without reporting CHF as a significant adverse event, though that population, while elderly, was ambulatory and living in the community.^[7]

Cortisol and ACTH elevation: compound-dependent

Not all secretagogues raise cortisol. This distinction gets lost in generalized safety discussions, and it matters.

GHRP-6 and GHRP-2 consistently elevate ACTH and cortisol alongside GH.^[3] In the Raun 1998 study, both compounds produced significant cortisol rises in swine models. The clinical implication: chronic GHRP-6 or GHRP-2 use could theoretically produce sustained hypothalamic-pituitary-adrenal axis stimulation, though no long-term human studies have tested this.

MK-677 shows a mixed cortisol profile. The Nass 2-year trial reported cortisol levels increasing by 47 nmol/L (1.7 mcg/dL) in MK-677 recipients (P = 0.020).^[2] Svensson's obese-male study found that initial cortisol elevation was transient; at 2 and 8 weeks, serum and urinary cortisol concentrations were not significantly different from placebo.^[4] This discrepancy may reflect differences in study duration, population, or methodology.

Ipamorelin stands alone in producing no cortisol elevation at any dose.^[3] This selectivity is the primary reason it has attracted clinical development interest for gastrointestinal applications where cortisol elevation would be counterproductive.

Prolactin, appetite, and fluid retention

Prolactin elevation is another off-target effect that varies by compound. MK-677 significantly increased prolactin after the initial dose in the Svensson trial, with the effect diminishing but persisting at 2 and 8 weeks.^[4] The initial prolactin spike was significantly greater than the increase seen after multiple doses, suggesting partial tachyphylaxis. Ipamorelin does not affect prolactin.^[3]

Appetite stimulation is inherent to the ghrelin receptor mechanism. MK-677 increased appetite in the Nass trial, though this effect subsided within a few months.^[2] GHRP-6 produces even stronger hunger. For cachexia applications, appetite stimulation is a benefit. For body composition optimization, it works against the goal.

Fluid retention appears across multiple trials. The Nass study reported transient mild lower-extremity edema.^[2] The White capromorelin study noted edema among adverse events.^[5] The mechanism is the same as with exogenous GH: growth hormone promotes sodium and water retention. In most healthy individuals, this is mild and self-limiting. In vulnerable populations (elderly, cardiac-compromised), it may contribute to the CHF signal described above.

Recreational use: the uncontrolled experiment

A 2022 case report by Cardaci and colleagues documented a 25-year-old male who self-administered LGD-4033 (10 mg) and MK-677 (15 mg) daily for 5 weeks.^[8] The metabolic disruption was substantial: HDL cholesterol dropped 36.4%, LDL rose 40%, triglycerides increased 39.2%, and liver enzymes (AST and ALT) rose 95.8% and 205% respectively. Free testosterone fell 85.7% and total testosterone dropped 62.3%. Bone mineral density decreased 2.1%.

Separating the effects of MK-677 from LGD-4033 (a SARM) is impossible in this case. The testosterone suppression and liver enzyme elevations are likely driven primarily by LGD-4033. But the case illustrates a broader pattern: recreational users often combine compounds, making it difficult to attribute specific harms to specific agents. MK-677 alone does not suppress testosterone, but combined with other compounds, it may compound metabolic stress in ways clinical trials of single agents would not predict.

Most biomarkers returned to baseline after the cycle ended, except total fat mass, bone area, total cholesterol, and LDL. Follicle-stimulating hormone remained below clinical reference values even post-cycle.^[8]

The sleep benefit that complicates the risk calculus

Not every secretagogue effect is adverse. MK-677 produced striking sleep improvements in the Copinschi 1997 study.^[10] In young subjects treated with 25 mg at bedtime for 7 days, stage IV (deep) sleep duration increased approximately 50%, and REM sleep increased more than 20% compared to placebo. The frequency of deviations from normal sleep dropped from 42% on placebo to 8% on MK-677. Older adults showed similar improvements: nearly 50% more REM sleep and decreased REM latency.

This finding complicates risk-benefit analysis because sleep quality affects metabolic health, cognitive function, and recovery. Whether the sleep benefits of GH peptides offset the glucose metabolism costs is an open question that no trial has been designed to answer.

What the Alzheimer's trial tells us about long-term safety

The Sevigny 2008 Alzheimer's disease trial is the largest single secretagogue study ever conducted: 563 patients randomized to MK-677 25 mg or placebo daily for 12 months.^[7] MK-677 achieved a 72.9% increase in serum IGF-1 at 12 months, confirming sustained target engagement. But there was zero benefit on any Alzheimer's disease endpoint: no effect on cognition (ADAS-Cog), daily function (ADCS-ADL), or clinical impression (CIBIC-plus).

From a safety perspective, the trial's value is its size and duration. 416 patients completed 12 months of treatment. The absence of alarming safety signals in this population provides some reassurance about medium-term tolerability in ambulatory elderly adults. But the trial was not designed or powered to detect differences in cancer incidence, cardiovascular events, or mortality.

What remains unknown

The Sigalos 2018 review identified the central gap in secretagogue safety data: "the safety of these compounds with long-term use, including evaluation of cancer incidence and mortality, is needed."^[1]

Cancer risk. IGF-1 is a growth factor. Elevated IGF-1 levels have been epidemiologically associated with increased risk of certain cancers, particularly prostate, breast, and colorectal. Secretagogues reliably raise IGF-1 by 40-73% in clinical trials. No trial has been long enough or large enough to determine whether this translates to increased cancer incidence. This is the single biggest unknown in the IGF-1 elevation and cancer risk literature.

Mortality. No secretagogue trial has reported all-cause mortality as a primary or secondary endpoint with adequate statistical power.

Tachyphylaxis. The Svensson trial noted that GH peaks after the initial MK-677 dose were significantly greater than after multiple doses, suggesting desensitization of the GH response.^[4] Whether this attenuation progresses further with chronic use, and whether it affects therapeutic benefit, is unclear.

Drug interactions. No systematic drug interaction studies have been published for any GH secretagogue. Given their effects on glucose metabolism and the HPA axis, interactions with diabetes medications, corticosteroids, and other hormonal agents are plausible but unstudied.

Population-specific risks. Nearly all trials enrolled either young healthy volunteers or elderly subjects. Data in middle-aged adults, women of reproductive age, adolescents, and individuals with pre-existing metabolic syndrome are sparse or absent. The long-term GH peptide safety evidence gap extends across every demographic.

The Bottom Line

Growth hormone secretagogues carry compound-specific risk profiles that range from the relatively clean selectivity of ipamorelin to the metabolic burden of chronic MK-677 use. Insulin resistance, fluid retention, and cortisol elevation are the best-documented adverse effects, though their severity varies by agent. The CHF signal in frail elderly patients remains unresolved. No secretagogue trial has lasted long enough to evaluate cancer risk, and the gap between what these compounds can do in the short term and what they might cost in the long term remains the defining uncertainty.

Frequently Asked Questions

What are the side effects of growth hormone secretagogues?

The most common side effects are increased appetite, mild fluid retention (edema), and impaired insulin sensitivity leading to elevated blood glucose. In the Nass 2008 two-year trial of MK-677, fasting glucose rose by 0.3 mmol/L and cortisol increased by 47 nmol/L. GHRP-6 and GHRP-2 also raise cortisol and ACTH levels, while ipamorelin does not produce these hormonal side effects.

Is MK-677 safe long term?

The longest controlled MK-677 trial lasted 2 years in 65 older adults. It showed sustained IGF-1 elevation and fat-free mass gains but also persistent insulin resistance and cortisol elevation. No trial has evaluated cancer incidence or mortality with long-term use. The Sigalos 2018 review concluded that long-term safety data, especially for cancer risk, remain needed.

Does MK-677 cause heart problems?

In a trial of elderly hip fracture patients, 6.5% of MK-677 recipients developed congestive heart failure versus 1.7% on placebo, leading to early termination. This signal has not appeared in trials of healthier populations. The mechanism likely involves GH-related fluid retention overwhelming compromised cardiac function in vulnerable individuals.

Is ipamorelin safer than GHRP-6?

Ipamorelin has a more selective safety profile than GHRP-6. In the Raun 1998 characterization study, ipamorelin released GH without increasing ACTH, cortisol, or prolactin, even at doses 200-fold above the effective threshold. GHRP-6 reliably elevates both cortisol and ACTH alongside GH, and also triggers stronger appetite stimulation through ghrelin pathways.

Do growth hormone secretagogues cause diabetes?

No secretagogue trial has reported diabetes as a direct outcome, but multiple trials show impaired glucose tolerance and reduced insulin sensitivity. Svensson's 1998 study of MK-677 in obese men found impaired oral glucose tolerance at 2 and 8 weeks despite normal fasting glucose. The concern is that prolonged use in metabolically vulnerable individuals could accelerate progression toward type 2 diabetes.

Are growth hormone secretagogues FDA approved?

No growth hormone secretagogue has received FDA approval for use as a GH-releasing agent. Over 11 compounds have entered human trials since the mid-1990s, but none has cleared regulatory approval. MK-677 advanced the furthest with Phase II and III trials but was not pursued for approval, likely due to the combination of modest efficacy and metabolic safety concerns.